Search Clinical Trials | Froedtert & MCW

Keyword

All of Us Research Program

Do you want to change the future of health? The Froedtert & MCW health network is part of the National Institutes of Health All of Us Research Program. It has a simple mission — speed up health research breakthroughs. To do this, All of Us is asking one million people to share their health information. Learn how you can help make a difference by joining the All of Us Research Program.

13 results for "Cancer" and "Gynecologic Cancers" and "Ovary"

A Phase 1 Study to Evaluate The Effect Of Hepatic Impairment On The Pharmacokinetics And Safety Of Lorlatinib In Advanced Cancer Patients

This is a phase 1 study in advanced cancer patients with varied hepatic fucntions to evaluate the potential effect of hepatic impairment on pharmacokinetics and safety of lorlatinib and provide dose recommendation for patients with hepatic impairment if possible.

Protocol No

PFIZER-B7461009

Sub Category

Hematologic/Blood Related Cancers

Early Phase/Multiple Disease Site Cancers

Thoracic Cancers

Sarcoma

Skin Cancers

Prostate and Urologic Cancers

Head and Neck Cancers

Gynecologic Cancers

Gastrointestinal Cancers

Endocrine Cancers

Breast Cancers

Randomized, Phase II/III Study of Pegylated Liposomal Doxorubicin and CTEP-Supplied Atezolizumab versus Pegylated Liposomal Doxorubicin/Bevacizumab and CTEP-Supplied Atezolizumab versus Pegylated Liposomal Doxorubicin/Bevacizumab in Platinum Resistant Ovarian Cancer

Pegylated Liposomal Doxorubicin Hydrochloride With Atezolizumab and/or Bevacizumab in Treating Patients With Recurrent Ovarian, Fallopian Tube, or Primary Peritoneal Cancer

Protocol No

NRG-GY009

Sub Category

Gynecologic Cancers

A Randomized Phase 3, Double-Blind Study of Chemotherapy With or
Without Pembrolizumab Followed by Maintenance With Olaparib or Placebo for the First- Line Treatment of BRCA non-mutated Advanced Epithelial Ovarian Cancer (EOC)

The purpose of this study is to assess the efficacy and safety of treatment with carboplatin/paclitaxel PLUS pembrolizumab (MK-3475) and maintenance olaparib (MK-7339) in women with epithelial ovarian cancer (EOC), fallopian tube cancer, or primary peritoneal cancer.

Protocol No

GOG-3036-MERCK-7339-001

Sub Category

Gynecologic Cancers

A Non-Randomized Prospective Clinical Trial Comparing the Non-Inferiority of Salpingectomy to Salpingo-oophorectomy to Reduce the Risk of Ovarian Cancer Among BRCA1 Carriers [SOROC]

To compare the non-inferiority of bilateral salpingectomy (BLS) with delayed oophorectomy to bilateral salpingo-oophorectomy (BSO) to reduce the risk of ovarian cancer among women with deleterious BRCA1 germline mutations.

Protocol No

NRG-CC008

Sub Category

Gynecologic Cancers

A Screening Protocol to Determine Tumor Antigen Expression and HLA Sub-Type for Eligibility Determination for Clinical Trials Evaluating the Safety and Efficacy of Autologous T Cells Expressing Enhanced TCRs in Subjects with Solid or Hematological Malignancies

Screening Protocol for Tumor Antigen Expression Profiling and HLA typing for Eligibility

Protocol No

ADP-0000-001-SCR

Sub Category

Gynecologic Cancers

Prostate and Urologic Cancers

Thoracic Cancers

Sarcoma

Skin Cancers

Head and Neck Cancers

Gastrointestinal Cancers

CELSION-201-17-201: Phase I-II Study Evaluating the Dosing, Safety, Efficacy and Biological Activity of Intraperitoneal GEN-1 (IL-12 Plasmid Formulated with PEG-PEI-Cholesterol Lipopolymer) Administered in Combination with Neoadjuvant Chemotherapy (NACT) in Patients Newly Diagnosed with Advanced Epithelial Ovarian, Fallopian Tube or Primary Peritoneal Cancer

The objective is to evaluate safety and compare progression free survival between subjects receiving neoadjuvant chemotherapy (NACT) plus GEN-1 versus NACT alone

Protocol No

CELSION-201-17-201

Sub Category

Gynecologic Cancers

A Phase 1 Dose Escalation Study to Assess Safety and Efficacy of ADP-A2M4CD8 in HLA-A2+ Subjects with MAGE-A4 Positive Tumors

ADP-A2M4CD8 in HLA-A2+ Subjects with MAGE-A4 Positive Tumors

Protocol No

ADP-0055-001-MAGE-A4-SURPASS

Sub Category

Gastrointestinal Cancers

Skin Cancers

Thoracic Cancers

Sarcoma

Prostate and Urologic Cancers

Head and Neck Cancers

Gynecologic Cancers

A Phase III, Randomized, Controlled, Double-Blind Study Evaluating the Safety of Two Doses of Apixaban for Secondary Prevention of Cancer Related Venous Thrombosis in Subjects Who Have Completed at Least Six Months of Anticoagulation Therapy

Apixaban in Preventing Secondary Cancer Related Venous Thrombosis in Cancer Patients Who Have Completed Anticoagulation Therapy

Protocol No

ACCRU-SC-1601

Sub Category

Hematologic/Blood Related Cancers

Early Phase/Multiple Disease Site Cancers

Thoracic Cancers

Sarcoma

Skin Cancers

Prostate and Urologic Cancers

Head and Neck Cancers

Gynecologic Cancers

Gastrointestinal Cancers

Eye/Orbital Cancers

Endocrine Cancers

Breast Cancers

Brain and Spine Cancers

A Multi-Center, Open Label Phase 1/2 Study Of Cyt-0851, An Oral Rad51 Inhibitor, In Patients With Relapsed/Refractory B-Cell Malignancies And Advanced Solid Tumors

his clinical trial is an interventional, active-treatment, open-label, multi-center, Phase 1/2 study. The study objectives are to assess the safety, tolerability and pharmacokinetics (PK) of the oral RAD51 inhibitor CYT-0851 in patients with relapsed/refractory B-cell malignancies and advanced solid tumors and to identify a recommended Phase 2 dose for evaluation in these patients.

Protocol No

CYTEIR-CYT-0851-01-REFMAL639

Sub Category

Hematologic/Blood Related Cancers

Early Phase/Multiple Disease Site Cancers

Sarcoma

Head and Neck Cancers

Gynecologic Cancers

Gastrointestinal Cancers

Breast Cancers

A Phase 1a/b Dose-Escalation Study Followed by Expansion Cohorts of NGM120, a GFRAL Antagonist Monoclonal Antibody Blocking GDF15 Signaling, in Subjects With Advanced Solid Tumors and Pancreatic Cancer Using Combination Therapy

NGM120, given as an injection, is designed to block a factor that is associated with cancer. NGM120 has shown in various animal models of cancer to reduce tumor size and improve symptoms of cancer.

Protocol No

NGM-18-0402

Sub Category

Gastrointestinal Cancers

Early Phase/Multiple Disease Site Cancers

Thoracic Cancers

Skin Cancers

Prostate and Urologic Cancers

Head and Neck Cancers

Gynecologic Cancers

A Phase 1b, Multicenter Study to Determine the Dose, Safety, Efficacy and Pharmacokinetics of TRK-950 When Used in Combinations with Selected Anti-Cancer Treatment Regimens in Patients with Selected Advanced Solid Tumors

A Study of TRK-950 in Combinations With Anti-Cancer Treatment Regimens in Patients With Advanced Solid Tumors

Protocol No

TORAY-950P1V02

Sub Category

Breast Cancers

Early Phase/Multiple Disease Site Cancers

Thoracic Cancers

Sarcoma

Skin Cancers

Prostate and Urologic Cancers

Head and Neck Cancers

Gynecologic Cancers

Gastrointestinal Cancers

A Phase Ib Study of Cobimetinib Administered In Combination with Niraparib, with or without Atezolizumab, to Patients with Advanced Platinum-Sensitive Ovarian Cancer

The purpose of this study is to evaluate the safety and efficacy of study drug cobimentinib given in combination with niraparib with or without atezolizumab in patients with platinum sensitive ovarian cancer

Protocol No

HOFFMANN-LAROCHE-YO40482

Sub Category

Gynecologic Cancers

The OVAL Study: A Randomized, Controlled, Double-Arm,Double-Blind, Multi-Center Study of Ofranergene Obadenovec (VB-111) Combined with Paclitaxel vs. Paclitaxel Combined with Placebo for theTreatment of Recurrent Platinum-Resistant Ovarian Cancer

To assess how well the combination of intravenous administration of VB-111 and paclitaxel compared to placebo and paclitaxel in patients with platinum resistant ovarian cancer as measured by Overall Survival.

Protocol No

GOG-3018-VBL-VB-111-701

Sub Category

Gynecologic Cancers